Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) FCF Margin (2016 - 2025)

Historic FCF Margin for Protalix BioTherapeutics (PLX) over the last 16 years, with Q3 2025 value amounting to 23.7%.

  • Protalix BioTherapeutics' FCF Margin fell 460700.0% to 23.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.91%, marking a year-over-year decrease of 346100.0%. This contributed to the annual value of 13.84% for FY2024, which is 176100.0% up from last year.
  • Protalix BioTherapeutics' FCF Margin amounted to 23.7% in Q3 2025, which was down 460700.0% from 35.4% recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' FCF Margin peaked at 97.01% during Q2 2021, and registered a low of 90.28% during Q1 2021.
  • Over the past 5 years, Protalix BioTherapeutics' median FCF Margin value was 32.77% (recorded in 2022), while the average stood at 19.01%.
  • In the last 5 years, Protalix BioTherapeutics' FCF Margin skyrocketed by 1703900bps in 2021 and then tumbled by -1825100bps in 2022.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' FCF Margin stood at 64.74% in 2021, then soared by 49bps to 32.77% in 2022, then skyrocketed by 197bps to 31.9% in 2023, then plummeted by -39bps to 19.57% in 2024, then crashed by -221bps to 23.7% in 2025.
  • Its FCF Margin was 23.7% in Q3 2025, compared to 35.4% in Q2 2025 and 54.24% in Q1 2025.